HYPR-Spectral PCT for Preclinical Imaging

用于临床前成像的 HYPR-Spectral PCT

• 批准号: 7534898
• 负责人: ROBERT A KRUGER
• 金额: $ 19.39万
• 依托单位: OPTOSONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-01 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7534898
• 关键词: 3-Dimensional; Acceleration; Algorithms; Angiogenesis Inhibitors; Animals; Blood flow; Caliber; Data; Devices; Disease; Disease Progression; Engineering; Goals; Hemoglobin; Hypoxia; Image; Imaging Device; Infrared Rays; Institution; Magnetic Resonance Angiography; Malignant Neoplasms; Measures; Modeling; Molecular Probes; Molecular Structure; Monitor; Mus; Noise; Pharmacologic Substance; Phase; Polychloroterphenyl Compounds; Prevention, Clinical, and Therapeutic Subcommittee; Process; Public Health; Radial; Research Personnel; Research Project Grants; Resolution; Scientist; Signal Transduction; Surface; Techniques; Therapeutic; Tissues; Xenograft procedure; data acquisition; design; design and construction; improved; in vivo; instrumentation; mouse model; novel; pre-clinical; reconstruction; response; tissue oxygenation; tumor

DESCRIPTION (provided by applicant): The long-term objective of this research project is to develop instrumentation and accelerated reconstruction techniques that will allow researchers to measure in vivo the heterogeneous hypoxic microenvironment of tumor models grown in mice, both xenografts and genetically engineered. To achieve these goals we will evaluate a new photoacoustic CT scanner designed to take advantage of acceleration techniques recently developed for phase contrast magnetic resonance angiography (MRA) and dynamic contrast enhanced MRA (DCE-MRA), which can significantly improve temporal resolution, without sacrificing signal to noise or spatial resolution. In Phase I we will design, construct and evaluate a new PCT scanner that will acquire a sparse set of 128 "projections" uniformly distributed over the surface of a hemisphere. Our goals are to achieve sub-second temporal resolution for dynamic studies and to acquire spectroscopic data over 16 wavelengths in as little as 1.6 seconds throughout a 20-mm-diameter imaging volume. Should we succeed, we will apply these techniques in vivo to mouse models of cancer in Phase II. PUBLIC HEALTH RELEVANCE: Scientists at pharmaceutical companies and academic institutions routinely employ preclinical imaging of small animals, especially mice, to study disease progression and monitor response to therapies. We propose to develop a novel, photoacoustic-imaging device that would allow researchers to interrogate the molecular structure of disease and assess response to therapy in a preclinical setting using near infrared radiation. This device would allow researchers to quantify hemoglobin concentration, blood flow, tissue oxygenation, and the accumulation of molecular probes in targeted tissues in small animals with excellent 3-D spatial and temporal resolution.

描述（由申请人提供）：该研究项目的长期目标是开发仪器和加速重建技术，使研究人员能够在体内测量在体内生长的肿瘤模型的异质性低氧微环境，包括异种移植物和基因设计。为了实现这些目标，我们将评估一种新的光声CT扫描仪，旨在利用最近开发的用于相比磁共振血管造影（MRA）（MRA）和动态对比度增强的MRA（DCE-MRA）的加速技术，可以显着改善时间分辨率，而无需牺牲信号到噪声或空间分辨率。在第一阶段，我们将设计，构建和评估一种新的PCT扫描仪，该扫描仪将获得一组稀疏的128个“投影”，均匀分布在半球表面上。我们的目标是实现动态研究的下时间分辨率，并在20毫米直径的成像量中仅在1.6秒内获得16个波长的光谱数据。如果我们成功，我们将在II期中将这些技术应用于癌症的小鼠模型。公共卫生相关性：制药公司和学术机构的科学家通常采用小动物（尤其是小鼠）的临床前成像来研究疾病的进展并监测对疗法的反应。我们建议开发一种新型的光声模仿装置，该设备将使研究人员能够使用近红外辐射审问疾病的分子结构，并评估临床前环境中对治疗的反应。该设备将使研究人员能够量化血红蛋白浓度，血流，组织氧合，以及具有出色3-D空间和时间分辨率的小动物中靶向组织中分子探针的积累。